NASDAQ: ACOGAlpha Cognition Inc Stock
$5.99-0.05 (-0.83%)
Updated Jun 12, 2026
ACOG Price
$5.99
Fair Value Price
$6.16
Market Cap
$130.43M
52 Week Low
$4.50
52 Week High
$11.54
P/E
-4.47x
P/B
2.27x
P/S
11.04x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.83M
Earnings
-$25.14M
Gross Margin
84.4%
Operating Margin
-224.05%
Profit Margin
-232.2%
Debt to Equity
0.21
Operating Cash Flow
-$30M
Beta
1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ACOG Overview
Alpha Cognition Inc. is a clinical-stage biopharmaceutical firm focused on creating therapies for neurological conditions such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Among its offerings is ZUNVEYL (benzgalantamine), intended for the management of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. The company is also progressing with other therapeutic programs, including ALPHA-0602, a gene therapy specifically for ALS, and ALPHA-0702 and ALPHA-0802, which are granulin epithelin motifs targeting various neurodegenerative disorders. Founded in 2000, the company initially operated as Crystal Bridge Enterprises Inc. before rebranding to Alpha Cognition Inc. in March 2021. Its corporate base is located in Vancouver, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACOG's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ACOG
Ranked#327 of 463
Ranked#327 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important ACOG news, forecast changes, insider trades & much more!
ACOG News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACOG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACOG ($5.99) is undervalued by 2.84% relative to our estimate of its Fair Value price of $6.16 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ACOG ($5.99) is not significantly undervalued (2.84%) relative to our estimate of its Fair Value price of $6.16 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACOG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACOG due diligence checks available for Premium users.
Valuation
ACOG fair value
Fair Value of ACOG stock based on Discounted Cash Flow (DCF)
Price
$5.99
Fair Value
$6.16
Undervalued by
2.84%
ACOG ($5.99) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACOG ($5.99) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACOG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACOG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.47x
Industry
16.53x
Market
14.15x
ACOG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.27x
Industry
4.85x
ACOG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACOG's financial health
Profit margin
Revenue
$3.5M
Net Income
-$6.5M
Profit Margin
-183.3%
ACOG's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ACOG's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$69.2M
Liabilities
$11.8M
Debt to equity
0.21
ACOG's short-term assets ($68.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACOG's short-term assets ($68.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACOG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.8M
Investing
-$1.3k
Financing
$800.0
ACOG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACOG vs Biotech Stocks
Alpha Cognition Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.